COVID-19 has devastated patient groups that prior to spring 2020 relied heavily on in-person events to raise funds, build communities and promote awareness. The cutbacks have set back scientific research,...

On the latest BioCentury This Week podcast, BioCentury editors discuss what Patrizia Cavazzoni’s appointment as permanent director of FDA’s Center for Drug Evaluation and Research means for the biopharma...

T cell engagers have dominated the bispecific antibody scene for the past five years, but the industry is starting to branch out into next-generation structures that offer new functions and potential improvements over first-generation compounds. ...

Synthetic lethality company Artios is the latest beneficiary of Novartis’ push toward radiotherapeutics, with the pharma paying $20 million up front for rights to three targets to be discovered by the biotech for use in...

Though nearly every Chinese CAR T developer is prioritizing autologous programs, the key to expanding access to the modality on the price-sensitive China market is likely to be the next-generation platforms...

Humanigen Inc. (NASDAQ:HGEN) shares rose 54% to $21.61 Monday after the company said top-line data showed lenzilumab improved survival without the need for mechanical ventilation in hospitalized patients...

As CEPI looks to prepare for the next pandemic, it has set a lofty goal to reduce to 100 days the time from sequencing the pathogen to a regulatory submission of a vaccine. But meeting...

Gene therapy developer Gyroscope has another $148 million to fuel further clinical testing of its lead program for age-related macular degeneration — and the Syncona-backed, U.K.-based company could...

The Senate confirmation of Xavier Becerra as HHS secretary and President Joe Biden’s announcement that he will nominate Dawn O’Connell as HHS assistant secretary for preparedness and response shine a bright...